Egyptian dermatologists were asked about the effect of COVID‐19 on prescription patterns, appointment rescheduling, therapy decisions, and telemedicine use.
A recent study examined the impact of COVID-19 on the delivery of care for patients with psoriasis and found that there were delays in starting medications and in follow-up appointments, and that patients frequently stopped their medication without consulting their physician.
The observational, cross‐sectional study took place in Egypt from October 6-23, 2020, via an online questionnaire.
The survey evaluated the effect of COVID‐19 on prescription patterns, appointment rescheduling, therapy decisions, and telemedicine use, as well as perception of the pandemic's effect on health care delivery. It comprised 29 questions (21 multiple‐choice questions, 5 checkbox questions, and 3 free‐response questions).
The survey was delivered via email and social media; 197 dermatologists responded.
Just under half (47%) of dermatologists recruited were not using biologics for psoriasis treatment. When they were used, interleukin (IL)‐17 inhibitors were the most frequently prescribed, and IL-12/IL-23 inhibitors were the least used.
Most dermatologists delayed putting most patients on biologics unless therapy was urgently needed; phototherapy was the least delayed treatment.
For patients already receiving biologics or immunosuppressive treatment, most dermatologists favored continuation of therapy.
Dermatologists also reported an increase in prescriptions for topical medications (79.2%), natural sunlight (28.4%), acitretin (26.9%), and home UVB (21.3%).
However, there was a statistically significant difference in stopping certain therapies: phototherapy and methotrexate were the least likely to be discontinued (53.8% and 42.6%, respectively), followed by cyclosporine (37.1%). Biologics were only discontinued 17.3% during this time (P < .001).
Of physicians who did start their patients on biologics during the pandemic, most (44.2%) do not perform SARS‐CoV‐2 PCR screening first. A little more than a quarter did so for patients with signs of illness, and 20.3% did it for all patients.
Intervals between face‐to‐face follow‐up visits were prolonged by 71.6% of dermatologists, who reported that this harmed patients psychologically, interfered with drug compliance, and worsened psoriasis manifestations.
More than half of providers said their patients discontinued treatment without checking with them, mainly for financial reasons, fear of receiving medications, and/or lack of accessibility to treatment.
About 60% of physicians said they used telemedicine during this time.
More than 75% of responders either agreed or strongly agreed that COVID‐19 had a negative impact on psoriasis care.
Reference
El-Komy MHM, Adbelnaby A, El-Kalioby M. How does COVID‐19 impact psoriasis practice, prescription patterns, and healthcare delivery for psoriasis patients? A cross‐sectional survey study. J Cosmet Dermatol. Published online April 3, 2021. doi:10.1111/jocd.14104
AA Unlikely to Cause Anxiety, Depression but May Be Affected by Mental Illness
May 7th 2024A Mendelian randomization study using genetic analysis found that alopecia areata (AA) increases the risk of anxiety and depression, but not the other way around, providing unique evidence for a causal link while adding to existing evidence.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
AUA Session Highlights the General Urologist’s Role in Gender-Affirming Care
May 7th 2024During her session, Polina Reyblat, MD, Kaiser Permanente Los Angeles Medical Center, highlighted best practices urologists should incorporate to make transgender and gender-diverse patients comfortable during physical exams and avoid retraumatization.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Access Denied: CMS’ Action Hurts Patients With Cancer in Rural America
May 6th 2024CMS rules hindered the access of rural patients with cancer to medically integrated pharmacies in 2023. The authors discuss the impact on equity in health care, emphasizing the need for regulatory change.
Read More
What Mass General Brigham Is Doing to Combat Prostate Cancer Disparities Among Men of Color
May 5th 2024Quoc-Dien Trinh, MD, MBA, chief of urology at Brigham & Women's Faulkner Hospital, highlighted successful efforts to improve prostate cancer care access for underserved communities in Massachusetts.
Read More